Sandra Leticia Crosara, MD
Infectious Disease · Mason City, IANPI 1922319656
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Johnson & Johnson at 28.4% of the total.
Across 11 payments — averaging $25.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$80
- Lifenet Health$61
- Smith+Nephew$54
- Organogenesis Inc.$35
- Astellas Pharma US Inc$20
- Insmed, Inc.$17
- plus $14 from 1 others
What the payments were for
- Food & beverage$26394%
- Education$176%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 1 | $80 |
| Lifenet Health | 4 | $61 |
| Smith+Nephew | 2 | $54 |
| Organogenesis Inc. | 1 | $35 |
| Astellas Pharma US Inc | 1 | $20 |
| Insmed, Inc. | 1 | $17 |
| AbbVie | 1 | $14 |
How this compares
$281 in reported general payments places this provider in the 70th percentile of 58 infectious disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 94 | $205,912 |
| TivicayDolutegravir Sodium | 55 | $121,344 |
| IsentressRaltegravir Potassium | 36 | $73,462 |
| DovatoDolutegravir Sodium/Lamivudine | 20 | $54,889 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $46,555 |
| Darunavir | 22 | $27,562 |
| Nafcillin Sodium | 18 | $11,078 |
| ErtapenemErtapenem Sodium | 13 | $8,604 |
| Daptomycin | 37 | $7,190 |
| Vancomycin Hcl | 47 | $5,893 |
| Cephalexin | 24 | $3,486 |
| CeftriaxoneCeftriaxone Sodium | 43 | $3,317 |
| Doxycycline Monohydrate | 63 | $2,024 |
| Cefazolin Sodium | 25 | $1,723 |
| Cefdinir | 31 | $1,641 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Mason City
- Ravi VemuriDes Moines$16K
- Louis KatzDavenport$12K
- Michael OhlIowa City$9K
- Upinder SinghIowa City$8K
- Karen BrustIowa City$4K
- Patricia WinokurIowa City$3K
- Daniel LampteySioux City$2K
- Ami PatelWaterloo$2K
- Bharat MotwaniDavenport$1K
- Aneesa AfrozeDes Moines$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.